ArticleClinical, cosmetic and investigational dermatology2026
Analysis of Predictors of Response Degree to Omalizumab in 124 Patients with Chronic Spontaneous Urticaria.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the key predictors of response degree of omalizumab in treating chronic spontaneous urticaria (CSU). Methods: A retrospective study was conducted on CSU patients treated with omalizumab in the dermatology department of Shijingshan Hospital, Beijing, from September 2023 to February 2025. Clinical data were collected via outpatient and telephone follow-ups, including demographics, medical history, triggering factors (eg, cold, heat, pressure, sunlight), serum total IgE levels, urticaria control test (UCT), and urticaria activity score 7 (UAS7) before and after treatment. Therapeutic efficacy was categorized as complete response (UAS7=0, UCT=16), markedly effective (UAS7<7, UCT=14-15), and effective (UAS7=8-16, UCT=12-13). Chi-square tests and binary logistic regression were used for statistical analysis. Results: Multivariate binary logistic regression indicated that triggering factors (none vs. multiple: OR=4.24, 95% CI 1.59-30.64; single vs. multiple: OR=11.41, 95% CI 1.96-66.40), family allergy history (none vs. present: OR=16.47, 95% CI 2.18-124.22), and antihistamine use prior to treatment (multiple vs. none: OR=12.29, 95% CI 2.89-169.48) were significant predictors of response degree (P<0.05). Age, disease duration, BMI, and serum total IgE showed no significant association with treatment outcomes. Conclusion: This single‑center retrospective study identifies clinical predictors of response degree among omalizumab‑treated CSU patients. Patients without family allergy history, with single or no triggering factors, and those using multiple antihistamines prior to treatment show higher degrees of response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.